434 related articles for article (PubMed ID: 17046205)
1. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
Abb J
Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
[No Abstract] [Full Text] [Related]
5. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
7. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
9. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
11. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
Jones RN; Fritsche TR; Sader HS; Ross JE
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
13. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin.
Raad II; Hanna HA; Hachem RY; Dvorak T; Arbuckle RB; Chaiban G; Rice LB
Antimicrob Agents Chemother; 2004 Sep; 48(9):3583-5. PubMed ID: 15328133
[TBL] [Abstract][Full Text] [Related]
14. [Comparative in vitro activity of daptomycin against gram-positive microorganisms: SENTRY surveillance program, Spain (2002-2006)].
Loza E; Morosini MI; Pascual A; Tubau F; Alcalá J; Liñares J; Hernández-Bello JR; Baquero F; Perea E; Martín R; Jones RN; Cantón R;
Enferm Infecc Microbiol Clin; 2008 Oct; 26(8):489-94. PubMed ID: 19094861
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I
Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
[TBL] [Abstract][Full Text] [Related]
16. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
17. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species.
Richter SS; Kealey DE; Murray CT; Heilmann KP; Coffman SL; Doern GV
J Antimicrob Chemother; 2003 Jul; 52(1):123-7. PubMed ID: 12805265
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
[TBL] [Abstract][Full Text] [Related]
19. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
20. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]